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ABSTRACT 
BARI 2D is a 2-by-2 factorial clinical trial identifying optimal therapies for patients with 
documented stable coronary artery disease and Type 2 Diabetes. Previous results of the BARI 
2D study indicated that there was a non-significant association between the therapies and 5-year 
survival outcomes. Our study hypothesizes that several intermediate variables may exist whose 
trajectories of improving or worsening in response to treatments act against each other leading to 
the previous non-significant associations. Before randomization, the participants were stratified 
to two types of revascularization - PCI or CABG. Then each participant was randomized to 
receive one cardiac therapy (prompt revascularization plus intensive medicine or intensive 
medicine alone), and also one glycemic therapy (insulin-sensitization or insulin-provision). Five 
intermediate outcomes BMI, SBP, HDL, LDL and Hba1c were studied. Linear regression was 
conducted to assess the difference of each intermediate outcome between therapies at Year 1 and 
at Year 3. Also conducted was a comparison of the trajectories over time by therapies using 
longitudinal repeated measures mixed models. In 2368 patients (mean age 62.4 years), the 
improvement of the intermediate outcomes was generally notable over the first year, and then 
slowly diminished over time. At both Year 1 and 3, insulin-provision resulted in higher BMI and 
Hba1c, and lower HDL than insulin-sensitization, irrespective of the assigned cardiac therapy 
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and revascularization stratum. Longitudinally, insulin-provision resulted in higher Hba1c, 
irrespective of the assigned cardiac therapy and revascularization stratum; and an interaction 
effect of the cardiac and glycemic therapies on BMI was found in CABG stratum. These results 
suggested that insulin-sensitization therapy is superior to insulin-provision therapy generally. In 
CABG stratum, the effect of cardiac therapy on BMI depends on the assignment of glycemic 
therapy. The public health significance of this study is that, though the cancelling-out hypotheses 
for these five intermediate variables may be overly optimistic, it involves a potentially 
illuminating perspective to explain the mechanisms through which the BARI 2D treatment 
therapies affect multiple intermediate outcomes. This in turn could also help inform and enhance 
the targeted adjuvant therapies, thus resulting in improved survival outcomes by better focusing 
on controlling the harmful intermediate variables. 
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1.0  LITERATURE REVIEW 
1.1 TYPE II DIABETES 
1.1.1 DEFINITION, EPIDEMIOLOGY, AND RISK FACTORS 
Diabetes is a chronic disease characterized by raised blood glucose. Globally, 10% of diabetes is 
Type 1 Diabetes, and 90% is Type 2 Diabetes. The main focus of the thesis is on Type 2 
Diabetes. The metabolic reason for Type 2 Diabetes is either due to the body’s lack of insulin 
production or due to its inefficient use of insulin. Type 2 Diabetes over time can result in serious 
complications such as neuropathy, nephropathy, blindness, heart attack, stroke, and amputation 
[1, 2]. Since the 1990s, the prevalence of Type 2 Diabetes has increased remarkably worldwide 
[3]. The most recent data show that in 2014, nearly 8% of adults globally lived with Type 2 
Diabetes; in 2012, about 1.5 million deaths worldwide were directly due to diabetes, which 
placed diabetes No. 8 in the worldwide leading causes of deaths list. Residents of low- and 
middle- income countries accounted for 80% of all diabetes-specific deaths. World Health 
Organization projected that the prevalence and mortality of diabetes will continue to rise such 
that, by the year 2030, diabetes will become the 7th leading cause of death throughout the world 
[3]. In the United States, 29.1 million people have diabetes, which comprises to 9.3% of the 
population. Among those, 8.1 million (27.8%) are undiagnosed [4]. 
2 
According to the Centers for Disease Control and Prevention (CDC) and the National 
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the risk factors for Type 2 
Diabetes include older age; being overweight or obese; having an individual history of impaired 
glucose tolerance, gestational diabetes or giving birth to at least one baby more than 9 pounds; 
having a family history of diabetes; races or ethnicities; lack of physical activity; high blood 
pressure, abnormal cholesterol levels, having polycystic ovary syndrome (PCOS), having 
acanthosis nigricans, or having blood vessel problems [2, 5]. The Centers for Disease Control 
and Prevention have a National Diabetes Prevention Program for people who have pre-diabetes 
or are at high risk for type 2 Diabetes. The aim of this structured lifestyle change program 
program is to prevent Type 2 Diabetes. People can participate in person or online [6]. The 
National Institute of Diabetes and Digestive and Kidney Diseases suggested a number of ways to 
prevent Type 2 Diabetes, which can be categorized by the following 5 aspects - meal portion size 
reduction, physical activity habit development, healthy food choices, emotional adjustment, and 
keeping a record of everyday food intake and physical activities [7].  
1.1.2 RISK FACTOR CONTROL GUIDELINES 
1.1.2.1 BMI 
According to the CDC, BMI between 18.5 and 24.9 (kg/m2) is normal weight. Below this level 
(<18.5 kg/m2) is underweight. Above this range are overweight (25-29.9 kg/m2) and obesity (30 
kg/m2 and above). [8] The American Diabetes Association recommends that for people who have 
diabetes, losing a few pounds weight through lifestyle change such as physical activity and 
healthy eating can help with diabetes control and decrease the risk of complications. [9] In the 
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BARI 2D study, all patients received counseling regarding smoking cessation, weight loss, and 
regular exercise, which were monitored regularly [10]. 
1.1.2.2 BLOOD PRESSURE 
For general population, 120/80 mmHg or lower is normal blood pressure; 140/90 mmHg or 
higher is defined as high blood pressure; levels in between are prehypertension [11]. According 
to JNC8 (2014), for the general population with hypertension, blood pressure goals differ by age, 
with 150/90 mmHg for people aged 60 years and older, and 140/90 mmHg for people aged 
below 60 years. For those with both hypertension and diabetes (but no CKD), the target goal is 
below 140/90 mmHg for all ages. This guideline was driven by a systematic review of clinical 
trial evidence [12, 13]. In contrast, according to JNC7 (2003) and JNC6 (1997), the blood 
pressure control goals for patients with both hypertension and diabetes were below 130/80 
mmHg and below 130/85 mmHg, respectively [14, 15]. The BARI 2D trial used the blood 
pressure ≤130/80 mm/Hg as the blood pressure control target [16]. 
1.1.2.3 LIPIDS 
According to the NCEP guideline (2001), for the general population, the recommended optimal 
lipids profile is LDL < 100 mg/dL, HDL between 40 and 60 mg/dL, and total cholesterol less 
than 200 mg/dL. For patients with coronary heart disease or diabetes, LDL control goal is LDL 
<100 mg/dL [17]. The LDL target from the NCEP guideline (2001) was the same as in the 1994 
NECP guideline [18, 19]. BARI 2D used LDL<100 mg/dL as the lipids control target [10]. 
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1.1.2.4 HBA1C 
For the general population, A1C equal to 6.5% is the clinical threshold. Equal or above this cut-
point indicates a diabetes diagnosis [20]. For non-pregnant patients who already diagnosed with 
diabetes, current guideline suggests A1C <7.0% is a proper blood glucose target [20]. BARI2D 
used Hba1c <7.0% as the blood glucose control target [21]. 
The current Hba1c target level was based on several fundamental trials. The UKPDS 
study indicated that intensive blood glucose control (Hba1c<7.0%) was better than less intensive 
control (Hba1c<7.9%) in terms of the risk of diabetic complications, especially microvascular 
complications [22]. The ACCORD trial found that targeting an A1C level of 7-7.9% was better 
than near normal levels (<6.0%) with respective to mortality and CVD risk [23]. The 
ADVANCE trial showcased that targeting HbA1c<6.5% was similar as targeting at 7-7.5% in 
terms of mortality and macrovascular risk [24]. The VA diabetes Trial showed that intensive 
therapy (Hba1c<7%) was superior to standard therapy (Hba1c 8-9%) in terms of modest effects 
on cardiovascular and microvascular outcomes [25]. 
1.1.3 MEDICATIONS FOR TYPE 2 DIABETES 
The medication therapies for Type 2 Diabetes can be categorized into insulin provision therapy 
and insulin sensitization therapy according to their mechanisms. The mechanism of insulin 
provision is increasing the insulin levels in the body. The mechanism of insulin sensitivity is 
improving the body’s response and the use of insulin [26]. 
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1.1.3.1 INSULIN PROVISION 
Two typical insulin provision medications are insulin and sulfonylureas, which are also the 
majority types of insulin provision medications administered in the BARI 2D study [27].  
There are several types of insulin depending on the onset-time, peak-time, and the 
duration it works in the blood. They are rapid-acting insulin, regular (also called short-acting 
insulin), intermediate-acting insulin, and long-acting insulin. The reacting time ranges from 15 
minutes to several hours. The peak hours range from 15 minutes to 10 or more hours. The 
duration of the insulin lowering blood glucose ranges from 2 to 24 hours. The most commonly 
used insulin is U-100 [28].  
Sulfonylureas can stimulate the pancreas to release more insulin. Sulfonylureas can only 
be effective when there still are some beta cells remaining [29, 30].  
1.1.3.2 INSULIN SENSITIZATION 
Two typical insulin sensitization medications are metformin and thiazolidinediones (TZDs). 
Metformin is the most commonly prescribed diabetic drug all over the world. It belongs 
to biguanides, a class of organic compounds. The American Diabetes Association (ADA) 
recommends metformin as the first-line oral treatment for people with newly diagnosed type 2 
Diabetes, unless they have some contraindications or other reasons that keep them from taking it 
[31]. 
Thiazolidinediones (TZDs) is another type of insulin-sensitization drugs, which works as 
an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more 
responsive to insulin [32]. Prescription of TZDs should be with caution, since the FDA (2002) 
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approved the changes to strengthen the labeling for TZDs regarding the cardiovascular risks that 
associated with TZDs [33].  
1.1.3.3 RISK FACTOR CONTROL COMPARISON OF MEDICATIONS FOR TYPE 2 
DIABETES 
Insulin, sulfonylureas, and TZDs use may lead to weight gain [34-36]. Metformin use may lead 
to weight loss [37, 38]. Insulin has beneficial effects on serum lipid profiles [39]. Sulfonylureas 
can slightly lower the levels of LDL and HDL, but the effect is small. [50]. Metformin decreases 
the blood lipids levels [40, 41]. The effects of TZDs on lipids profiles differ by the agent used 
[42]. Insulin use elevated blood pressure [43]. Sulfonylurea initiation was related with an 
elevated SBP compared to metformin, and BMI may be functioning as the potential mediator 
[44]. Metformin may decrease the blood pressure. The evidence was inconsistent [45]. TZDs 
may decrease both SBP and DBP, but the change is in a small scale [46]. Insulin use leads to a 
decrease in HbA1c by 1.5-2.5% [47]. Sulfonylureas use leads to a decrease in HbA1c by 1.5% 
[47]. Metformin was expected to decrease HbA1C by 1.5-2.0% [45]. TZDs were expected to 
lead a decrease in HbA1C by 0.5-1.4% [47]. Insulin and sulfonylureas are associated with more 
frequent episodes of hypoglycemia than metformin or TZDs [48]. A combination therapy of 
sulfonylurea plus insulin is being used less frequently [49]. There was a lack of longitudinal 
evidence for comparing effects of insulin-provision therapy vs. insulin-sensitization therapy on 
changes and control of BMI, lipids status, blood pressure, and glycemic profiles over time. 
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1.2 CORONARY ARTERY DISEASE 
1.2.1 DEFINITION, EPIDEMIOLOGY, AND RISK FACTORS 
Cardiovascular disease (CVD), also known as heart disease, is a class of heart and blood vessel 
diseases. There are several types of CVD including coronary artery diseases (CAD), heart valve 
diseases, heart failure, and arrhythmia [51]. Cardiovascular disease usually caused by narrowed 
blood vessels that could lead to chest pain (angina), or even blood block that could lead to heart 
attack, or stroke [52]. As the top one cause of death due to disease, CVDs showed high 
prevalence and high severity. In 2012, there were 17.5 million people that died from CVDs in the 
world, which represented a third of the total deaths during that year. Among those 17.5 million 
deaths, 42% were caused by coronary heart disease and 38% were caused by stroke. More than 
75% of CVD deaths occur in low- and middle-income countries. CVD is also a major cause of 
death (37%) among people who died under the age of 70 due to non-communicable diseases [50].  
Coronary artery disease (CAD), also known as coronary heart disease (CHD), is related 
with impaired coronary arteries, which lowers the blood flow that carries the oxygen and 
nutrients to the heart. The development of CAD is related with the formation of cholesterol-
containing deposits (plaque) in the arteries and or inflammation. This process can progress over 
many years, and is known as atherosclerosis [53].  
With the plaque building up, the blood vessels become narrower over time, and the 
severity of symptoms increases. Angina occurs when the blood flow to heart through arteries is 
decreased. It is represented as chest pain or discomfort in the surrounding area, and a shortness 
of breath. Myocardial infarction (MI), commonly known as heart attack, occurs when the blood 
flow is blocked. A sudden rupture of the plaque can cause a block. Without a quick treatment, a 
8 
heart attack can result in severe medical problems even death. CHD over time can impair the 
heart muscle and could cause heart failure and arrhythmias [54]. 
1.2.2 REVASCULARIZATIONS FOR CORONARY ARTERY DISEASE 
1.2.2.1 PERCUTANEOUS CORONARY INTERVENTION (PCI) 
Percutaneous coronary intervention (PCI or PTCA) is a non-surgical type of revascularization 
treating coronary artery disease. The procedure is to use a balloon catheter to broaden a blocked 
coronary artery from within. After the procedure, there will be more room for blood to go 
through, and transport the oxygen and nutrients to the heart muscle [55].  
1.2.2.2 CORONARY ARTERY BYPASS GRAFTING (CABG) 
Coronary artery bypass grafting (CABG) is a surgical type of revascularization treating serious 
coronary artery disease. The surgery is to use a healthy artery or vein from the patient he/herself 
to graft and bypass the blocked section of the coronary artery. This new vessel will serve as the 
new path for blood flow to the heart muscle [56]. 
1.2.2.3 COMPARISONS BETWEEN REVASCULARIZATION AND INTENSIVE 
MEDICAL THERAPY ALONE IN CONTROL OF RISK FACTORS 
There was comparatively limited evidence comparing the effect of revascularization with PCI or 
CABG overall vs. intensive antianginal medical therapy alone on changes and control of BMI, 
lipids status, blood pressure, and glycemic profiles.   
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1.3 SUMMARY OF LITERATURE REVIEW 
For Type 2 Diabetes, the major risk factors include overweight or obesity, unhealthy diet, 
physical inactivity, family history, ethnicity, older age, high blood pressure, and abnormal lipid 
profiles. The current guidelines for patients with both T2D and CAD suggested that the target 
levels of risk factors are: Hba1<7.0%, BP<140/90 mmHg, LDL<100 mg/dL, and losing a few 
pounds weight. Two common types of drugs treating Type 2 Diabetes are insulin-provision drugs 
and insulin-sensitization drugs. Insulin, sulfonylureas, metformin and TZDs were different in 
mechanisms and in their abilities of controlling risk factors. There exists evidence of insulin-
provision therapy verses insulin-sensitization therapy on risk factor controls at baseline and at 
Year 3, but not longitudinally. 
For CAD, the major risk factors include unhealthy diet and obesity, lack of physical 
activity, smoking, and excessive use of alcohol, elevated blood pressure, increased blood lipids, 
and elevated glucose. Two common types of revascularization are PCI and CABG. A gap 
remains in comparing the effectiveness of risk factors control between prompt revascularization 
with intensive medical therapy verses intensive medical therapy alone. 
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1.4 BARI 2D CLINICAL TRIAL 
1.4.1.1 DESIGN OF THE BARI 2D CLINICAL TRIAL 
The BARI 2D study implemented a 2-by-2 factorial design, with two cardiac therapies: either 
prompt revascularization with intensive medical therapy or intensive medical therapy alone; and 
two glycemic therapies:  either insulin-sensitization therapy or insulin-provision therapy. The 
intensive medical therapy for management of coronary risk factors included the following 
medications: adrenergic blockers, angiotensin converting enzyme inhibitors, and aspirin for all 
patients unless contraindicated. Insulin-providing strategy included medications as follows: 
sulfonylurea drugs, repaglinide, nateglinide, or insulin itself. Insulin-sensitizing strategy included 
medications as follows: thiazolidinediones (TZDs) or metformin. All patients had targets of 
Hba1c<7.0% and uniform control of hypertension (BP<130/80 mmHg), dyslipidemia (LDL<100 
mg/dL), and obesity following recommended medical guidelines. Before randomization, the 
participants were stratified to percutaneous coronary intervention (PCI) or coronary-artery 
bypass grafting (CABG) stratum according to the prior choice of revascularization recommended 
by the cardiologist as the more appropriate intervention. BARI 2D recruited 2368 eligible and 
enrolled patients with both type 2 diabetes and stable ischemic heart disease at 49 clinical centers 
in North America, South America, and Europe.  Patients were followed for an average of 5.3 
years. The primary outcome was 5-year mortality. The secondary outcome was major 
cardiovascular events, which was represented by a composite of death, myocardial infarction, or 
stroke [10].  
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1.4.2 MAIN RESULTS OF THE BARI 2D TRIAL 
A core paper regarding the primary outcomes by the BARI 2D Study Group (2009) evaluated 
and compared the effect of two cardiac therapies and two glycemic therapies on patients’ 5-year 
survival rate and major cardiovascular events. During the average follow-up of 5 years, no 
statistically significant difference was found in the rates of death and major cardiovascular 
events between the two cardiac therapy groups, or between glycemic therapy groups. In PCI 
stratum, no significant difference was found between the cardiac therapy and glycemic therapy 
groups. In CABG stratum, revascularization was better than medical therapy alone in terms of 
the rate of major cardiovascular events (P=0.002 for interaction between CABG stratum and 
cardiac treatment groups) [10]. 
Bittner V et al (2015) based on the BARI 2D clinical trial data and analyzed the 
feasibility and effects of controlling multiple risk factors (RFs) in their target levels of the 
protocol guidelines through intensive medical therapy on cardiovascular events and mortality. A 
non-randomized analysis of 2,265 patients’ mortality/cardiovascular events and control of 6 RFs 
(no smoking, low density lipoprotein cholesterol <130 mg/dl, triglycerides <150 mg/dl, blood 
pressure [systolic <130 mm Hg; diastolic <80 mm Hg], glycosylated hemoglobin <7%) in the 
BARI 2D trial was conducted. The number of RFs at 5 years had shown been improved a lot 
from baseline (4.2 ± 1.3 vs. 3.5 ± 1.4, p < 0.0001). Cox models were conducted with the 
following covariates: time-varying number of RFs in control, baseline number of RFs in control, 
other clinical characteristics, and group assignments. The RFs control status during the trial was 
highly associated with the survival outcome (global p = 0.0010) and composite endpoint (global 
p = 0.0035). Specifically, patients with less than 2 RFs in control during the five years follow-up 
had an approximately 2-fold higher risk of death (HR=2.0, 95% CI=1.3-3.3, p=0.0031) and of 
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the composite endpoint (HR=1.7, 95% CI=1.2-2.5; p=0.0043), compared with the patients with 
all six RFs under control. Their findings supported the feasibility and effectiveness of 
simultaneous control of multiple RFs through protocol-guided intensive medical therapy on 
reducing the rate of cardiovascular morbidity and mortality in patients with coronary disease and 
Type 2 Diabetes [57]. 
1.5 AIMS AND HYPOTHESIS 
Based on the literature review, I will assess the trajectories of most important/well known 
modifiable risk factors for both T2D and CAD in the BARI 2D clinical trial. The selected 
intermediate variables were HDL, LDL, SBP, Hba1c, and BMI. 
Aim 1: To assess differences between insulin-provision therapy and insulin-sensitization therapy 
in their control of the intermediate risk factors at Year 1 and at Year 3 and longitudinally    
Hypothesis 1 Insulin-provision therapy will be associated with higher BMI and SBP, and 
lower HDL and Hba1c, and a similar LDL, as compared to insulin-sensitization therapy, 
at both Year 1 and Year 3 and longitudinally.   
Aim 2: (exploratory) To assess the strength of association of revascularization with control of the 
intermediate risk factors at both Year 1 and Year 3 and longitudinally.    
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2.0  ANALYSIS PLAN 
2.1 STUDY DESIGN AND PARTICIPANTS 
The BARI 2D dataset we used in the analyses was a public use “deidentified” dataset available at 
BioLINCC including 2368 patients with both type 2 diabetes and stable documented coronary 
artery disease. The average follow-up time was 5.3 years. Before randomization, the participants 
were stratified to a percutaneous coronary intervention (PCI) or coronary-artery bypass-grafting 
(CABG) stratum according to the prior choice of revascularization as the more appropriate 
intervention. Each participant received either prompt revascularization with intensive cardiac 
medical therapy or intensive cardiac medical therapy alone. Each participant was then randomly 
assigned to one of two glycemic therapies: either insulin-sensitization therapy or insulin-
provision therapy. This resulted in four arms per revascularization strata (Figure 1).  The primary 
outcome was 5-year mortality. The secondary outcome was major cardiovascular events, which 
was represented as a composite of death, myocardial infarction, or stroke. Previous results of the 
BARI 2D trial indicated there was a non-significant association between the assigned treatments 
and 5-year survival outcomes. 
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2.2. INTERMEDIATE VARIABLES 
BMI, SBP, HDL, LDL, and Hba1c were selected as intermediate variables (also called process 
outcomes). Each of these risk factors was measured at baseline and annually for a maximum of 5 
years of follow-up period. BMI was calculated by the equation weight (in kilograms) over height 
squared (in meters). One-minute resting blood pressure was measured with participants in the 
seated position. The systolic and diastolic blood pressures were based on an average of two 
sitting blood pressures. LDL-cholesterol, HDL-cholesterol, and HbA1c levels were measured 
from blood samples collected at baseline and annually, and were analyzed at the BARI 2D core 
Biochemistry Laboratory.  
2.3 STATISTICAL ANALYSIS 
Linear regression analyses were conducted to assess whether there were differences in the 
intermediate outcomes between treatment groups at Year 1 (short term) and at Year 3 (longer 
term) after the baseline. Also conducted was a comparison of the trajectories over time by 
treatment group using a longitudinal repeated measures mixed model that included all five years 
of follow-up with an AIC-selected best fitting heterogeneous autoregressive covariance structure 
plus random subject-level intercept.  
All models were adjusted for baseline, age and sex. Analyses were conducted separately 
within each revascularization stratum. Revascularization and insulin provision were entered as 
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separate terms in all models. Their interaction term was also entered and tested for presence of 
potential synergistic or antagonistic effects. If a significant interaction was found, the four 
intervention arms within that stratum were modeled as separate groups. The interaction of time 
and treatments were also tested. 
2.4 RESULTS 
The BARI 2D dataset used in the analyses was a public use “deidentified” dataset available at 
BioLINCC. The total sample size was 2368 patients, with 1605 patients in the PCI stratum and 
763 patients in the CABG stratum, respectively (Figure 1). The mean age (SD) of the total 
population was 62.4 (8.9) years, with a range of 40 to 80 years. At baseline, the PCI 
revascularization stratum was younger, with a higher proportion of females and non-whites. The 
PCI stratum also generally had higher BMI, lower SBP and HbA1c than patients in the CABG 
stratum. Mean HDL and LDL were similar. There was no major imbalance by randomized 
treatment assignment (Table 1). 
Graphically, it was revealed that the risk factors generally and notably improved over the 
first year after baseline, after which the benefit for most of the risk factors slowly diminished 
over time (Figure 2).  
The linear regression models, focusing on Year 1 or Year 3 adjusted for baseline, showed 
that revascularization (either PCI or CABG) when combined with either type of diabetic medical 
therapy generally did not further improve control of the risk factors (all p > 0.061). Table 2 also 
showed that insulin provision resulted in higher BMI and Hba1c, and lower HDL in the PCI and 
CABG strata at both Year 1 and Year 3. Adjusted for baseline levels, generally across all 
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intervention arms, females showed statistically significant less improvement than males in their 
LDL and SBP in the short term (Year 1) and longer term (Year 3). Females showed better 
improvement than males in HDL at both of these time points. For each model, the interactions of 
time and treatments were also tested and none were found to be significant (Table 2). 
Longitudinal analyses showed that several risk-factor trajectories differed depending on 
the revascularization procedure recommended by the cardiologist. Revascularization with PCI 
(vs. medication therapy) was not statistically different for BMI, HDL, LDL, SBP, and Hba1c in 
terms of their mean trajectories (p > 0.386), which indicated longitudinally that revascularization 
with PCI when combined with diabetic medical therapy generally did not further improve control 
of the risk factors. The effect of revascularization with CABG (vs. intensive medical therapy 
alone) on BMI depends on the glycemic therapy that the revascularization with CABG was 
combined with (interaction term p=0.032). The combination of revascularization with CABG 
plus insulin-sensitization therapy was associated with a lower BMI (-1.16 kg/m2, p=0.021) as 
compared to the combination of intensive medical therapy alone plus insulin-sensitization 
therapy. The risk-factor trajectories also differed depending on the type of glycemic therapy. In 
the PCI stratum, participants randomized to insulin provision had a higher mean level of BMI 
(1.03 kg/m2, p= 0.014) and a higher mean level of Hba1c (0.22%, p=0.006) across all 5 years 
than those randomized to insulin-sensitization therapy. In the CABG strata, participants 
randomized to insulin provision had a higher mean level of Hba1c (0.43%, p < .0001) across all 
5 years than those randomized to insulin-sensitization therapy. The effect of insulin provision 
(vs. insulin sensitization) on BMI depends on the cardiac randomization group (revascularization 
with CABG vs. intensive medical alone) (interaction term p=0.032). For each model, the 
interaction of time and treatment was also tested and none were found to be significant (Table 3).  
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The significant revascularization by insulin provision interaction term in Table 3 for the 
BMI outcome in the CABG stratum (p=0.032) suggests a further analysis. Table 4 focused on 
trajectories of the BMI among the four arms of the CABG stratum with MedIS as the referent 
group. The combination of revascularization with CABG and insulin-sensitization therapy 
(RevIS) was associated with a significant lower BMI (-1.16 kg/m2) as compared to the 
combination of intensive medical and insulin-sensitization therapy (i.e. MedIS, set as the referent 
group) (p=0.020). The combination of revascularization with CABG and insulin provision 
(RevIP), and the combination of intensive medical therapy alone plus insulin provision (MedIP), 
were not statistically different from the combination of intensive medical alone and insulin-
sensitization therapy (MedIS) in terms of the longitudinal BMI (p=0.833 and p=0.346, 
respectively). Table 5 similarly focuses on the differences of the trajectories of BMI among the 
four arms in the CABG stratum with RevIP as the referent group. The combination of 
revascularization with CABG and insulin-sensitization therapy (RevIS) was associated with a 
significant lower BMI (-1.05 kg/m2) as compared to the combination of revascularization with 
CABG and insulin-provision therapy (RevIP). The combination of intensive medical therapy 
alone plus insulin-sensitization therapy (MedIS), and the combination of intensive medical 
therapy alone plus insulin-provision therapy (MedIP), were not statistically different from the 
combination of revascularization with CABG and insulin-provision therapy (RevIP, set as the 
referent group) in terms of the longitudinal BMI (p=0.833 and p=0.468, respectively).  
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2.5 DISCUSSIONS AND CONCLUSIONS  
Our study suggested that different glycemic therapies (insulin-provisioning vs. insulin-
sensitizing) were associated with significantly different levels of BMI, HDL, and Hba1c at both 
short-term (Year 1) and longer-term (Year 3). Insulin-sensitizing therapy was superior in terms 
of controlling BMI, HDL, and Hba1c. In other words, with insulin-sensitizing therapy, the blood 
glucose and weight control targets were achieved more efficiently than with insulin-provisioning 
therapy. The reason Year 3 was chosen as the longer-term time-window, instead of Year 5, is 
that at Year 5 the sample size was relatively small (for most intermediate outcomes, the 
remaining sample size was about 50% in Year 5 vs. 70% in Year 3). 
Longitudinally, the linear mixed model is a relatively robust model, so we included all 
five years of follow-up data irrespective of the retention rate at later time-points. It was revealed 
that the superior effects of insulin-sensitizing therapy in controlling risk factors still existed in 
Hba1c levels irrespective of the revascularization strata. The uniformly superior risk-factor 
control ability of insulin-sensitizing (vs. insulin-provisioning) for the BMI outcome existed only 
in the PCI stratum. In contrast, in the CABG stratum, the effect of glycemic therapy (insulin-
provisioning vs. insulin-sensitizing) on BMI control depended on the assigned cardiac therapy 
(either prompt revascularization or intensive medical only). This may due to the fact that linear 
mixed model provided more statistically power and can detect smaller differences than linear 
regression model at one time point. To further address this issue, instead of using two separate 
(cardiac and glycemic therapy) terms and their interaction term, we compared the four therapy-
arms (RevIP, RevIS, MedIP, MedIS) in the CABG stratum.  
A more interpretable version of the effect of insulin-provisioning therapy (vs. insulin-
sensitizing therapy) on BMI over time showed that the revascularization with CABG plus 
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insulin-sensitization therapy (RevIS) had a significantly lower BMI, as compared to the intensive 
medical therapy alone plus insulin-sensitization therapy (MedIS, the referent group). The other 
two therapy groups were not statistically significant from this referent group. The 
revascularization with CABG plus insulin-sensitizing therapy group (RevIS) had a significantly 
lower BMI, as compared to the revascularization with CABG plus insulin-provisioning therapy 
(RevIP, the referent group). The other two therapy groups were not statistically significant from 
this referent group.  
It was also suggested that the interaction effect between time and therapies might exist 
since the longitudinal trajectories figures showed a “fan-shape” over time generally for all risk 
factors. However, the interaction terms of time, treated as categorical variable, and therapies 
were assessed, and they were not statistically significant. Therefore time interaction terms were 
not included in the models. Future studies may try a “random slope” in addition to the current 
“random intercept” to assess if the new model fits better and if the interaction of continuous time 
and treatment was significant. By including therapy arm specific time-slopes, this modeling 
approach has the potential to reveal increasingly better rates of control over time for certain risk 
factors by some of the cardiac-glycemic control therapy combinations.  
It is interesting that, although the Bittner et al. study suggested that the number of risk 
factors under control has a significant effect on the survival outcome and major cardiovascular 
outcome [57], and that our study suggested the treatment therapies have significantly different 
effect on some of those risk factors, none of the survival outcomes or cardiovascular clinical 
outcomes differed by treatment groups according to the core paper of the BARI 2D study by 
Frye et al. [10]. A potential explanation is that the risk factors were functioning as the mediators 
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between the treatments and outcomes, but the survival analyses were not statistically powered 
enough to detect mediation effects based on the number of events. 
The main strength of this study is that a gap in the literature was partially filled by the 
longitudinal analyses of the effect of revascularization with PCI or CABG (vs. intensive medical 
therapy alone) and the effect of insulin-sensitization therapy (vs. insulin-provision therapy) on 
control of risk factors including BMI, HDL, LDL, SBP, and Hba1c over 5 years. Insulin-
sensitizing therapy was shown to be superior vs insulin-provisioning therapy longitudinally in 
terms of controlling BMI and Hba1c even when factoring in that all patients in all therapy arms 
were monitored and had goals of Hba1c <7.0% and uniform control of hypertension, 
dyslipidemia and obesity following recommended medical guidelines. Another strength is that 
the hypotheses are innovative. The hypotheses involve a potentially illuminating perspective to 
explain the mechanisms through which the BARI 2D treatment therapies affect multiple 
intermediate outcomes, which in turn could also help enhance the targeted adjuvant therapies 
resulting in improved survival outcomes by focusing on treating or controlling the harmful 
intermediate variables. Although the assessed intermediate variables in this study did not show 
the compensating effects against one another, it is still a good example for other researchers to 
refer when further analyzing other potential intermediate variables. 
The limitations include the following points. Firstly, the categorical form of the time 
variable limited the power of time interaction assessments. Secondly, other potential 
intermediate variables could be assessed regarding my hypotheses.  
The conclusion for this study is that the original hypothesis of a cancellation of effects 
between the five risk factors (BMI, HDL, LDL, SBP, and Hba1c) was not supported. Insulin-
sensitization therapy showed generally superior risk-factor control ability than insulin-
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provisioning therapy. Further analyses can include more risk factors (i.e. renal risk factors, CRP) 
in the analyses to assess the effect of the treatments on control of those. 
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APPENDIX: FIGURES 
 
Figure 1. Enrollment Flow Chart, BARI 2D 
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Figure 2. Longitudinal Trajectories of BMI Over 5 Years of Follow-up Time 
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Figure 3. Longitudinal Trajectories of HDL Over 5 Years of Follow-up Time 
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Figure 4. Longitudinal Trajectories of LDL Over 5 Years of Follow-up Time 
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Figure 5. Longitudinal Trajectories of SBP Over 5 Years of Follow-up Time  
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Figure 6. Longitudinal Trajectories of Hba1c Over 5 Years of Follow-up Time 
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APPENDIX: TABLES 
Table 1. Demographic Characteristic and Intermediate Variables Levels at Baseline by 
Stratum 
 
  
PCI CABG 
 P 
N=1605 N=763 
Age, mean (SD) 61.5 (9.0) 62.8 (8.3) 0.0003 
Female, N (%) 517 (32.2) 185 (24.3) <. 0001 
Non-White, N (%) 510 (31.8) 192 (25.2) 0.001 
BMI, mean (SD) 32.3 (6.1) 30.4 (4.9) <. 0001 
HDL, mean (SD) 38.4 (10.6) 37.8 (9.4) 0.1970 
LDL, mean (SD) 95.4 (32.8) 97.5 (34.7) 0.1791 
SBP, mean (SD) 130.7 (19.7) 133.9 (20.6) 0.0003 
HbA1c (%), mean (SD) 7.6 (1.6) 7.7 (1.7) 0.0478 
SD standard deviation 
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Table 2. Linear Regression Models for Intermediate Outcomes at Year 1 (short term) and Year 3 (longer term) by Stratum 
Intermediate 
Variables  Demogr char & basel lev 
PCI CABG  
Year 1  Year 3  Year 1  Year 3   
Coef SE P Coef SE P Coef SE P Coef SE P  
BMI 
Sex 0.20 0.12 0.094 0.10 0.17 0.538 -0.01 0.18 0.946 0.01 0.24 0.956  
Age -0.04 0.01 <.0001 -0.07 0.01 <.0001 -0.05 0.01 <.0001 -0.05 0.01 0.000  
Revasc  0.11 0.11 0.319 0.09 0.15 0.568 0.16 0.15 0.301 0.38 0.20 0.061  
Insul Prov. 0.58 0.11 <.0001 0.63 0.15 <.0001 0.81 0.15 <.0001 0.63 0.20 0.002  
Baseline Level 0.95 0.01 <.0001 0.92 0.01 <.0001 0.92 0.02 <.0001 0.93 0.02 <.0001  
HDL 
Sex 1.64 0.50 0.001 1.76 0.57 0.002 1.84 0.74 0.014 2.01 0.95 0.034  
Age 0.07 0.03 0.008 0.03 0.03 0.268 -0.06 0.04 0.113 -0.02 0.05 0.735  
Revasc  0.50 0.44 0.253 0.54 0.50 0.286 0.49 0.61 0.427 0.87 0.79 0.269  
Insul Prov. -1.78 0.44 <.0001 -1.98 0.50 <.0001 -2.22 0.61 0.000 -2.44 0.79 0.002  
Baseline Level 0.72 0.02 <.0001 0.74 0.03 <.0001 0.68 0.03 <.0001 0.65 0.04 <.0001  
LDL 
Sex 7.03 1.66 <.0001 5.65 1.70 0.001 4.69 2.37 0.049 2.57 2.64 0.329  
Age -0.35 0.09 0.000 -0.16 0.09 0.081 -0.30 0.13 0.017 -0.23 0.14 0.090  
Revasc  0.55 1.55 0.722 0.71 1.57 0.653 -1.27 2.03 0.531 3.03 2.23 0.174  
Insul Prov. -0.07 1.54 0.963 -0.09 1.57 0.953 0.73 2.02 0.718 1.37 2.23 0.538  
Baseline Level 0.25 0.02 <.0001 0.18 0.02 <.0001 0.23 0.03 <.0001 0.21 0.03 <.0001  
SBP 
Sex 2.70 0.92 0.004 2.55 0.94 0.007 2.34 1.35 0.083 2.38 1.40 0.090  
Age 0.15 0.05 0.002 0.17 0.05 0.001 0.07 0.07 0.298 0.07 0.07 0.351  
Revasc  0.84 0.86 0.328 0.73 0.87 0.406 -0.52 1.13 0.644 1.07 1.18 0.367  
Insul Prov. 0.02 0.86 0.985 0.20 0.87 0.815 -1.13 1.12 0.312 -0.03 1.17 0.977  
Baseline Level 0.27 0.02 <.0001 0.20 0.02 <.0001 0.24 0.03 <.0001 0.17 0.03 <.0001 
Hba1c 
Sex 0.07 0.07 0.347 0.05 0.08 0.542 0.11 0.10 0.271 0.03 0.12 0.819  
Age -0.01 0.00 0.130 -0.02 0.00 <.0001 -0.01 0.01 0.114 -0.02 0.01 0.001  
Revasc  -0.09 0.07 0.164 -0.04 0.07 0.595 -0.09 0.08 0.271 -0.15 0.10 0.133  
Insul Prov. 0.29 0.07 <.0001 0.49 0.07 <.0001 0.31 0.08 0.000 0.44 0.10 <.0001  
Baseline Level 0.46 0.02 <.0001 0.41 0.02 <.0001 0.38 0.03 <.0001 0.34 0.03 <.0001  
Revasc  Revascularization vs. Medicine Therapy (referent),    Insul Prov.   Insulin Provision (IP) vs. Insulin Sensitization (IS)  (referent)  
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Table 3. Linear Mixed Models for Trajectories of Intermediate Outcomes Over All five Years of Follow-up Time by Stratum 
 
Intermediate 
Variables 
Treatment Groups 
and Other Covariates 
PCI CABG 
Coef SE P Coef SE P 
BMI 
sex 2.08 0.32 <.0001 -0.08 0.41 0.839 
age -0.15 0.02 <.0001 -0.08 0.02 0.000 
Revasc  0.36 0.42 0.394 -1.16 0.50 0.021 
Insul Prov. 1.03 0.42 0.014 -0.47 0.50 0.346 
Revasc * Insul Prov. -0.75 0.60 0.205 1.52 0.71 0.032 
Year Annual terms Annual  terms Annual  terms Annual  terms Annual  terms Annual  terms 
HDL 
sex 7.09 0.51 <.0001 4.99 0.74 <.0001 
age 0.10 0.03 0.000 0.05 0.04 0.184 
Revasc  0.14 0.67 0.841 0.87 0.89 0.328 
Insul Prov. -0.33 0.67 0.625 -0.66 0.89 0.458 
Revasc * Insul Prov. -0.76 0.96 0.428 -1.55 1.26 0.220 
Year Annual  terms Annual  terms Annual  terms Annual  terms Annual  terms Annual  terms 
LDL 
sex 8.82 1.10 <.0001 7.37 1.73 <.0001 
age -0.37 0.06 <.0001 -0.43 0.09 <.0001 
Revasc  0.77 1.44 0.595 1.08 2.09 0.606 
Insul Prov. 1.14 1.44 0.427 -0.67 2.07 0.748 
Revasc * Insul Prov. -2.05 2.05 0.316 -0.26 2.96 0.930 
Year Annual  terms Annual  terms Annual  terms Annual  terms Annual  terms Annual  terms 
SBP 
sex 3.41 0.62 <.0001 4.50 0.90 <.0001 
age 0.19 0.03 <.0001 0.16 0.05 0.001 
Revasc  0.35 0.82 0.667 -1.85 1.09 0.089 
Insul Prov. 0.94 0.82 0.250 -1.35 1.07 0.209 
Revasc * Insul Prov. -1.29 1.16 0.268 0.68 1.53 0.655 
Year Annual  terms Annual  terms Annual  terms Annual  terms Annual  terms Annual  terms 
Hba1c 
sex 0.30 0.06 <.0001 0.30 0.09 0.001 
age -0.04 0.00 <.0001 -0.04 0.00 <.0001 
Revasc  -0.07 0.08 0.386 -0.12 0.11 0.276 
Insul Prov. 0.22 0.08 0.006 0.43 0.11 <.0001 
Revasc * Insul Prov. 0.14 0.12 0.219 -0.07 0.16 0.637 
Year Annual  terms Annual  terms Annual  terms Annual  terms Annual  terms Annual  terms 
Revasc  Revascularization vs. Medicine Therapy (referent),     Insul Prov.   Insulin Provision (IS) vs. Insulin Sensitization  (referent) 
Revasc * Diab Meds Therapy   Interaction term 
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Table 4. Linear Mixed Model for Trajectories of BMI Control Over All Five Years of 
Follow-up Time by Specific Treatment Group (ref=MedIS)  
Intermediate 
Outcomes 
Treatment 
Groups and 
Other 
Covariates 
CABG 
Coef SE P 
BMI 
sex -0.08 0.41 0.839 
age -0.08 0.02 0.000 
MedIP -0.47 0.49 0.346 
RevIP -0.11 0.50 0.833 
RevIS -1.16 0.50 0.020 
MedIS (ref) ref ref ref 
Year Annual terms 
Annual 
terms 
Annual 
terms  
    
Table 5. Linear Mixed Model for Trajectories of BMI Control Over All Five Years of 
Follow-up Time by Specific Treatment Group (ref=RevIP) 
 
Intermediate 
Outcomes 
Treatment 
Groups and 
Other 
Covariates 
CABG 
Coef SE P 
BMI 
sex -0.08 0.41 0.839 
age -0.08 0.02 0.000 
MedIS 0.11 0.50 0.833 
MedIP -0.36 0.50 0.468 
RevIS -1.05 0.50 0.037 
RevIP (ref) ref ref ref 
Year Annual terms 
Annual 
terms 
Annual 
terms 
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